Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
21.98 ^USD	-0.54%		-3.60%	-26.66%

Apr. 16	Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	MT
Apr. 11	Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	MT

Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?

March 05, 2024 at 09:32 am EST

NEW YORK, March 5, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCEA, CASI, CRDL, GERN, and RCKT.

InvestorsObserver (PRNewsfoto/InvestorsObserver)

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

OCEA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=OCEA&prnumber=202403054
CASI: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CASI&prnumber=202403054
CRDL: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CRDL&prnumber=202403054
GERN: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=GERN&prnumber=202403054
RCKT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=RCKT&prnumber=202403054

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-ocean-biomedical-casi-pharmaceuticals-cardiol-therapeutics-geron-or-rocket-pharmaceuticals-302079949.html

SOURCE InvestorsObserver

Latest news about Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	Apr. 16	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	Apr. 11	MT
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	Apr. 02	MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target	Apr. 02	MT
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	Apr. 02	CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	Mar. 26	MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	Mar. 26	CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	Mar. 26	CI
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating	Mar. 01	MT
Rocket Pharmaceuticals Q4 Loss Narrows	Feb. 26	MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 25	CI
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	Feb. 13	MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi	Feb. 13	DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	Feb. 13	CI
Transcript : Rocket Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM	Jan. 08
Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Warrants of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Stock Options of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director	Dec. 12	CI
Rocket Pharmaceuticals Insider Sold Shares Worth $450,646, According to a Recent SEC Filing	Nov. 17	MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 05	CI
Cantor Fitzgerald Initiates Rocket Pharmaceuticals With Overweight Rating, Price Target is $65	23-10-24	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $315,744, According to a Recent SEC Filing	23-10-03	MT

Chart Rocket Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.98 USD

Average target price

50.31 USD

Spread / Average Target

+128.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ROCKET PHARMACEUTICALS, INC.	-26.66%	1.99B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs